Normothermic ex vivo kidney perfusion (NEVKP) represents a novel approach for graft preservation and functional improvement in kidney transplantation. We investigated whether NEVKP also allows graft quality assessment before transplantation.
| INTRODUCTION
A major challenge in solid organ transplantation is the severe graft shortage. Extending the donor pool by using organs of lower quality represents a promising option to shorten the recipient's waiting list.
Kidneys from extended criteria donors (ECD) and donation after circulatory death (DCD) donors are increasingly used worldwide, providing good posttransplantation outcomes.
1
ECDs have risk factors for poor function after transplantation such as higher donor age, a history of hypertension, increased serum creatinine, and death from cerebrovascular accident.
2 DCD donors are burdened with an additional warm ischemia (WI) injury before organ recovery. 2 Assessment of graft quality in these marginal graft categories is difficult, and exact criteria predicting graft injury and function after transplantation are lacking. 3 As a consequence, high graft discard rates are reported for all types of marginal renal grafts, even for those that might be appropriate for transplantation. The 2013
Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients (OPTN/SRTR) Annual Kidney Data Report highlighted the percentage of kidneys that were recovered with the intention to transplant but were finally not transplanted. Ten percent of SCD grafts were declined, while 45% of ECD grafts offered were declined. About 18% of donation after brain death (DBD) kidneys and 20% DCD kidneys were declined. 4 Discard rates for combined ECD/ DCD grafts were highest and are reported to be about 51% in the United States.
5
Current decision criteria, mainly based on donor characteristics, potentially result in inappropriate discard of suitable renal grafts. Another approach to reducing inappropriate discard of kidneys potentially suitable for transplantation involves graft assessment in real time, during preservation, before transplantation. While static cold storage (SCS) provides limited potential for graft quality assessment, machine perfusion allows the investigation of perfusion characteristics and perfusate biomarkers as potential predictors for renal graft outcome. 3 Perfusion at normothermic temperatures maintains the graft metabolism during the preservation period, which offers the opportunity to evaluate graft function and injury before transplantation. [6] [7] [8] [9] Normothermic machine perfusion of renal grafts was recently described by Hosgood and Nicholson 7, 10 and by our group, [11] [12] [13] demonstrating superior graft preservation compared with SCS. Using a porcine model of heterotopic kidney autotransplantation, here we report the potential of normothermic ex vivo kidney perfusion (NEVKP)
for renal graft quality assessment before transplantation.
| METHODS

| Study design
We investigated whether continuous NEVKP can be used to assess renal graft quality during preservation and to predict kidney function posttransplantation. Therefore, noninjured heart-beating donor (HBD) kidneys (no WI, group A), moderately injured DCD kidneys (30 minutes of WI, group B), and severely injured DCD kidneys (60 minutes of WI, group C) were preserved with 8 hours of continuous NEVKP ( Figure 1 ). After contralateral kidney resection and heterotopic graft autotransplantation, the pigs were followed for 3 days. Perfusion characteristics and clinically available biomarkers obtained during NEVKP were correlated with peak serum creatinine levels, a marker for posttransplantation renal graft function.
11-13
| Animals
Male Yorkshire pigs weighing 30 kg were used. Species-adapted housing with water and food ad libitum was provided. All animals received humane care in compliance with the "Principles of Laboratory
Animal Care" formulated by the National Society for Medical Research and the "Guide for the Care of Laboratory Animals" published by the National Institutes of Health.
| Kidney retrieval
Kidney retrieval was performed as previously described. 14 
| Normothermic ex vivo kidney perfusion
NEVKP was performed as previously described elsewhere. 15 Briefly, an S3 heart-lung machine and neonatal cardiopulmonary by- 
| Kidney transplantation
During the last hour of graft preservation, recovered pigs were reanesthetized with an intravenous propofol administration. After intubation, anesthesia was maintained by using 1.5% isoflurane per inhalation and 15 mL/h propofol intravenous. Repeat laparotomy, contralateral kidney resection, and heterotopic renal autotransplantation were performed. Operative and perioperative procedures, drug administration, and follow-up were conducted as described elsewhere.
14 Animals were followed for 3 days and then killed while under anesthesia for tissue collection.
| Whole blood, serum, and urine measurements
Blood gas analysis (RAPIDPoint 500 Systems; Siemens AG, Berlin, 
| Histology
Renal 
| Statistics
| Cumulative urine production during NEVKP was not significantly different between groups and did not correlate with posttransplantation outcomes
Cumulative urine production at the end of NEVKP was not significantly different between groups with 60 ± 21 mL in group A, 83 ± 54 mL in group B, and 49 ± 32 mL in group C (P = .394) and did not correlate with renal graft function after transplantation (P = .312).
| Physiologic acid-base homeostasis during NEVKP correlates with improved renal function after transplantation
Acid-base homeostasis, assessed by measuring pH, HCO 3 -, and base excess (BE) of the perfusate, was significantly different among groups during the first hours of NEVKP. The pH was highly significantly different between groups at hours 1 and 2 (P < .001) and significantly different at hours 3 and 4 (P < .05) with least acidotic values for noninjured grafts from group A ( Figure 3A) . HCO 3 -demonstrated highly significant differences at hour 2 (P < .001) and significant differences at hours 1, 3, and 4 (P < .05) ( Figure 3B) ; BE was significantly different from hour 1 until hour 3 (P < .001) and at hour 4 (P < .05) ( Figure 3C Values are presented as mean ± SD. *Significant differences. DCD, donation after circulatory death; HBD, heart-beating donor
| Injury markers obtained in perfusate during NEVKP determine graft viability
AST measured in the perfusate showed significant differences at hours 5, 6, and 7 of perfusion. A positive correlation between AST and peak serum creatinine was found for hours 2 to 7, with the highest correlation at hour 7 of 0.884 (P < .001). Perfusate LDH did not demonstrate significant differences at any time (P > .05). Of note, perfusate electrolyte levels of sodium and potassium were highly significantly different at hour 1 of perfusion (P < .001 and P = .001). Further, perfusate chloride levels were highly significant different at hours 1 and 2 (P < .001) and significantly different at hours 3 to 5 (P < .05).
| Posttransplantation kidney function deteriorated with increasing WI times
Posttransplantation, renal function deteriorated significantly with increasing WI times ( Figure 5 ). Peak serum creatinine was lowest in HBD grafts from group A (3.0 ± 1.1 mg/dL on POD 1), moderately elevated in group B (4.0 ± 1.2 mg/dL on POD 1), and highest in group C (7.2 ± 1.7 mg/dL on POD 2) (P < .001). Similarly, peak serum BUN was significantly different among the 3 groups (group A 27.0 ± 6.2 mg/ dL on POD 1, group B 30.8 ± 7.3 mg/dL on POD 1, and group C 61.8 ± 12.1 mg/dL on POD 2; P = .021). In addition, serum creatinine and serum BUN levels were different among groups at POD 1 (P = .013
and P = .021), POD 2 (P < .001 and P < .001), and POD 3 (P = .004 and <.001). Serum potassium levels were different among groups on POD 1 (group A 3.75 ± 0.42 mmol/L, group B 3.71 ± 0.25 mmol/L, group C 4.21 ± 0.20 mmol/L) and POD 2 (group A 3.80 ± 0.13 mmol/L, group B 3.75 ± 0.34 mmol/L, group C 4.34 ± 0.51 mmol/L) after transplantation (P = .043 and P = .045, respectively). There were no differences in serum sodium, calcium, or chloride levels (P > .05). Histologic assessment revealed no significant differences among groups at baseline or 30 minutes after reperfusion (P > .05) but significant differences in tubular injury at day 3 after transplantation (P = .044) ( Table 1 ).
| DISCUSSION
Continuous NEVKP demonstrated feasibility and safety in HBD pig kidney transplantation 11 and superiority over SCS in DCD pig kidney transplantation. 12, 13 The present study demonstrates the potential F I G U R E 5 Serum creatinine levels after heterotopic renal autotransplantation (Auto-KTx). Values are presented as mean ± SD. *Significant differences among groups (P < .05). DCD, donation after circulatory death; HBD, heart-beating donor; NEVKP, normothermic ex vivo kidney perfusion Thirty high-power fields (HPFs) were scored on a scale of 0 to 3 for tubular injury and inflammation. In addition, apoptotic cells were counted on terminal deoxynucleotidyl transferase dUTP nick-end labeling-stained slides in 50 HPFs. Data are shown as median (range). DCD, donation after circulatory death; HBD, heart-beating donor; NEVKP, normothermic ex vivo kidney perfusion.
T A B L E 1 Histopathologic injury scores assessed on periodic acid-Schifs-stained slides in the 3 experimental groups at baseline, 30 minutes after reperfusion, and 3 days after transplantation NEVKP bears for graft quality assessment before transplantation. Recipients (SRTR), reported no significant reduction in kidney discard rates (18.1% versus 18.3%, respectively). 18 Further criteria such as macroscopic graft appearance, ischemia times, and preimplantation biopsy scores, which can be assessed during SCS preservation, bear limited potential to predict graft outcome after transplantation. In contrast, assessing metabolic kidney function during normothermic kidney machine perfusion might represent a novel, more-comprehensive strategy to predict the outcome of marginal grafts.
Hypothermic machine perfusion is increasingly used for renal graft preservation in the United States ( Figure 6 ). Recent studies, systematic reviews, and meta-analyses indicate significant improvements over SCS, especially reduced rates of delayed graft function (DGF). 19, 20 Further, several studies investigated the value of hypothermic ma- represented severe ATN, in terms of both peak serum creatinine and time necessary for repair. 29 Despite potential implications to use this 32 In addition to using ex vivo normothermic perfusion (EVNP) for graft preservation, Hosgood and coworkers also investigated its potential as a platform for renal graft assessment. 33 Seventy-four human kidneys deemed unsuitable for transplantation after retrieval underwent 60 minutes of EVNP at 36°C. The macroscopic appearance, renal blood flow, and urinary output were incorporated into an EVNP assessment score, ranging from 1 ("highest quality") to 5 ("lowest quality"). This was applied to a series of 36 kidneys transplanted after 1 hour of EVNP. These kidneys scored between 1 and 3 and all were transplanted successfully without PNF.
DGF and estimated glomerular filtration rate were significantly different among groups, suggesting the potential use of EVNP for graft assessment. 34 Further, EVNP was used to investigate ureteric blood supply before transplantation. found by other groups such as oxidative index, vascular index, or quantitative urine production might not be applicable in our setup, which makes the current study relevant for clinical scenarios. Another limitation is that no group of animals was included in this study that had severe renal injury leading to primary graft failure. Although this would be necessary for developing injury scores and estimate threshold, this group was purposefully not included due to ethical considerations.
For NEVKP in clinical practice, a VS predicting graft outcome should be developed in a human setting, based on retrospectively obtained clinical data, as animal models will not suffice for this clinical purpose.
Perfusion characteristics and perfusate biomarkers will not reflect the same levels in human and animal scenarios. An additional limitation is that no creatinine was added to the system, precluding direct measurement of the creatinine clearance. However, the low urine produc- 
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